文献速递妇科

白蛋白结合型紫杉醇与紫杉醇在铂耐药卵巢癌中的比较结局(COMPASS研究)

Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS).
PubMed 文献 · Gynecol Oncol · 2025-12-05

COMPASS是一项回顾性观察研究,利用美国Flatiron健康研究数据库数据,比较白蛋白结合型紫杉醇与紫杉醇单药治疗铂耐药卵巢癌的真实世界疗效与安全性。共纳入225例患者(白蛋白结合型紫杉醇67例,紫杉醇158例),经逆概率治疗加权后,两组真实世界无进展生存期和总生存期相当;白蛋白结合型紫杉醇组周围神经病变发生率(14%)为紫杉醇组(28%)的一半。

要点

  • 白蛋白结合型紫杉醇与紫杉醇单药在铂耐药卵巢癌中真实世界无进展生存期和总生存期相当。
  • 白蛋白结合型紫杉醇组周围神经病变发生率14%,为紫杉醇组28%的一半。
  • 白蛋白结合型紫杉醇组贫血、腹泻、乏力、输液反应、恶心呕吐、血小板减少发生率较低,中性粒细胞减少、发热性中性粒细胞减少、白细胞减少发生率较高。

核心结论

  • 白蛋白结合型紫杉醇与紫杉醇疗效相当,且周围神经病变发生率更低,提示白蛋白结合型紫杉醇是铂耐药卵巢癌患者的有效治疗选择及临床试验的相关对照。

研究设计与样本

  • COMPASS为回顾性观察研究,使用美国Flatiron健康研究数据库中去标识化的铂耐药卵巢癌患者数据,比较白蛋白结合型紫杉醇与紫杉醇单药治疗。
  • 共纳入225例患者,其中67例接受白蛋白结合型紫杉醇,158例接受紫杉醇单药治疗。
  • 采用逆概率治疗加权(IPTW)方法对队列进行加权。

主要发现

  • 真实世界无进展生存期:未校正HR 1.11(95%CI 0.82-1.49),IPTW校正HR 1.03(95%CI 0.66-1.63)。
  • 总生存期:未校正HR 0.95(95%CI 0.69-1.3),IPTW校正HR 1.11(95%CI 0.79-1.56)。
  • 使用双重稳健IPTW的敏感性分析显示结果一致。
  • 白蛋白结合型紫杉醇组贫血、腹泻、乏力、输液相关反应、恶心/呕吐、周围神经病变和血小板减少的发生率低于紫杉醇组,而中性粒细胞减少、发热性中性粒细胞减少和白细胞减少的发生率高于紫杉醇组。
  • 白蛋白结合型紫杉醇组周围神经病变频率为14%,紫杉醇组为28%,前者为后者的一半。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the real-world effectiveness and safety of monotherapy nab-paclitaxel and paclitaxel in patients with platinum-resistant ovarian cancer (PROC). METHODS: COMPASS is a retrospective, observational study using deidentified patient data from the longitudinal US Flatiron Health Research Database in patients with PROC who received monotherapy nab-paclitaxel or paclitaxel. Real-world progression-free survival (rwPFS), overall survival (OS), and prespecified real-world adverse events (rwAEs) were assessed. Cohorts were weighted by the inverse probability of treatment (IPTW) approach. RESULTS: Of the 225 patients included, 67 received nab-paclitaxel and 158 received paclitaxel monotherapy. Most patients were > 65 years old with an Eastern Cooperative Oncology Group performance status of 0-1 and were treated in the community setting. rwPFS and OS were comparable across cohorts (rwPFS: unadjusted hazard ratio [HR],1.11; 95 % CI, 0.82-1.49; IPTW-adjusted HR, 1.03; 95 % CI, 0.66-1.63; OS: unadjusted HR, 0.95; 95 % CI, 0.69-1.3; IPTW-adjusted HR, 1.11; 95 % CI, 0.79-1.56). A sensitivity analysis using doubly robust IPTW showed consistent results. Incidence rates of anemia, diarrhea, fatigue, infusion-related reactions, nausea/vomiting, peripheral neuropathy, and thrombocytopenia were lower with nab-paclitaxel than with paclitaxel, while those of neutropenia, febrile neutropenia, and leukopenia were higher. The frequency of peripheral neuropathy in the nab-paclitaxel cohort (14 %) was half that of the paclitaxel cohort (28 %). The observed trends in rwAEs persisted when adjusted for duration of exposure. CONCLUSIONS: Nab-paclitaxel demonstrated comparable effectiveness to paclitaxel with a lower rate of peripheral neuropathy, suggesting that nab-paclitaxel is an effective treatment option and a relevant comparator for clinical trials of patients with PROC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Shahin MS, Mathur R, Parthan A, et al. Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS). Gynecol Oncol. 2025. PMID: 41351946. doi:10.1016/j.ygyno.2025.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。